MEI Pharma, Inc. (NASDAQ:MEIP)

CAPS Rating: 1 out of 5

A development stage company, engaged in the clinical development of the anti-cancer drug phenoxodiol.

Results 1 - 9 of 9

Recs

1
Member Avatar zzlangerhans (99.73) Submitted: 2/14/2013 10:45:10 PM : Underperform Start Price: $6.20 MEIP Score: -14.22

Thanks to a low float after a reverse split, MEI stock is bobbing around like a cork in the ocean. After cutting loose from Novogen and their failed plant flavonoid technology, MEI needed to find a new reason to exist and continue paying inflated salaries to management. Lo and behold, the company acquired oral HDAC inhibitor Pracinostat from S*Bio for 0.5M in stock and contingent payments. Suddenly, Pracinostat is the next great thing in hematologic malignancy, with MEI heavily PR'ing preliminary phase II data for Pracinostat in MDS that was generated before they bought the drug. Did S*Bio management suddenly go insane, divesting a multibillion dollar drug to a nonentity microcap biopharma for pocket change? I'm skeptical. But this is baby bio and there's no accounting for short-term market irrationality. Grab a seat and lets see what happens ...

Recs

0
Member Avatar scrubs62074 (88.85) Submitted: 2/13/2013 11:17:30 AM : Outperform Start Price: $5.03 MEIP Score: +46.02

High Volume Breakout on 02/13/13

Recs

0
Member Avatar tcampbellla (72.93) Submitted: 9/10/2008 3:37:08 PM : Underperform Start Price: $16.08 MEIP Score: +102.43

Did this go up for any logical reason?

Recs

0
Member Avatar sausagegirl (< 20) Submitted: 4/16/2008 12:10:27 PM : Outperform Start Price: $17.58 MEIP Score: -94.67

It won't be fastest growing company but it will be one that steadily rises due to the fact the more and more people are trying to find the cure for cancer with any kind of research and development this company is ahead of some of the games that are being played right now. Anyone and everyone is throwing in their hats to get a piece of cancer research because of the fact that everyone wants to be recognized as the person or company that cured cancer.

Recs

0
Member Avatar equalfuture (< 20) Submitted: 4/12/2008 8:39:54 PM : Outperform Start Price: $17.76 MEIP Score: -98.05

Tharlow likes it...

Recs

0
Member Avatar TopCanoeist (78.63) Submitted: 4/11/2008 11:02:47 AM : Outperform Start Price: $15.96 MEIP Score: -90.55

Potential drug in pipeline for "orphan" cancer (orphan as per FDA) (pancreatic cancer) ref. news below

Many potential drugs are discarded during clinical test but a breaktrhrough drug can reaps substantial rewards!

Therefore follow-up updates closely at every stage of clinical tests!
-------------------------------------------------------
NEW CANAAN, CT--(MARKET WIRE)--Mar 25, 2008 -- Triphendiol was recently granted orphan drug status by the U.S. Food and Drug Administration (FDA) for malignant melanoma and for the treatment of cholangiocarcinoma, bile duct cancer.

Recs

0
Member Avatar Biotech2008 (26.23) Submitted: 1/4/2008 10:06:38 PM : Outperform Start Price: $16.26 MEIP Score: -84.82

applefoot @2.86

Recs

1
Member Avatar tharlow (64.51) Submitted: 11/9/2007 12:05:47 AM : Outperform Start Price: $18.00 MEIP Score: -86.93

This company has a portfolio of next-generation cancer drugs with blockbuster potential. Look no further for the next Genentech.

Recs

0
Member Avatar RBBioContest06 (50.64) Submitted: 5/31/2006 10:29:35 PM : Outperform Start Price: $19.02 MEIP Score: -112.08

Picked by GeezerRob

Results 1 - 9 of 9

Featured Broker Partners


Advertisement